Effect of statin treatment for familial hypercholesterolaemia on life assurance: Results of consecutive surveys in 1990 and 2002

British Medical Journal

Volumn 328, Issue 7438, 2004, Pages 500-501

  Neil, H A W ^a   Hammond, T ^b   Mant, D ^b   Humphries, S E ^c  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ANAMNESIS; CASE REPORT; CLINICAL EXAMINATION; DRUG EFFECT; FAMILIAL HYPERCHOLESTEROLEMIA; FOLLOW UP; HEALTH CARE POLICY; HEALTH INSURANCE; HEALTH SURVEY; HUMAN; LABORATORY TEST; LIFE EXPECTANCY; MALE; MORTALITY; PATIENT; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE; RISK ASSESSMENT; SHORT SURVEY;

EID: 1442274587     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.328.7438.500     Document Type: Short Survey

References (5)

1. Mayor S. UK insurers agree five-year ban on using genetic tests. BMJ 2001;323:1021.
2. Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 1999;142:105-12.
3. Neil HAW, Hammond T, Huxley R, Matthews DR, Humphries SE. Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. BMJ 2000;321:148.
4. Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinaemia. Circulation 1974;49:476-488.
5. Neil HAW, Mant D. Cholesterol screening and life assurance. BMJ 1991;302:891-3.